BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7. [PMID: 19996335 DOI: 10.1136/thx.2009.113498] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Puente Maestú L, García de Pedro J. Lung Function Tests in Clinical Decision-Making. Archivos de Bronconeumología (English Edition) 2012;48:161-9. [DOI: 10.1016/j.arbr.2011.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Lo KH, Donohue J, Judson MA, Wu Y, Barnathan ES, Baughman RP; Sarcoidosis T-48 Investigators. The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis. Lung 2020;198:917-24. [PMID: 32979072 DOI: 10.1007/s00408-020-00394-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Faverio P, De Giacomi F, Bonaiti G, Stainer A, Sardella L, Pellegrino G, Sferrazza Papa GF, Bini F, Bodini BD, Carone M, Annoni S, Messinesi G, Pesci A. Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights. Int J Med Sci 2019;16:967-80. [PMID: 31341410 DOI: 10.7150/ijms.32752] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Vainshelboim B, Fox BD, Kramer MR, Izhakian S, Gershman E, Oliveira J. Short-Term Improvement in Physical Activity and Body Composition After Supervised Exercise Training Program in Idiopathic Pulmonary Fibrosis. Arch Phys Med Rehabil 2016;97:788-97. [PMID: 26869288 DOI: 10.1016/j.apmr.2016.01.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
5 King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials. Am J Respir Crit Care Med 2014;189:825-31. [DOI: 10.1164/rccm.201311-1951oc] [Cited by in Crossref: 84] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
6 Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H, Glaspole IN. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology 2017;22:1459-72. [PMID: 28891101 DOI: 10.1111/resp.13163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
7 Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431-440. [PMID: 20935110 DOI: 10.1164/rccm.201006-0894CI] [Cited by in Crossref: 847] [Cited by in F6Publishing: 431] [Article Influence: 70.6] [Reference Citation Analysis]
8 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-1769. [PMID: 21571362 DOI: 10.1016/s0140-6736(11)60405-4] [Cited by in Crossref: 1123] [Cited by in F6Publishing: 482] [Article Influence: 102.1] [Reference Citation Analysis]
9 Parisien-la Salle S, Abel Rivest E, Boucher VG, Lalande-gauthier M, Morisset J, Manganas H, Poirier C, Comtois A, Dubé B. Effects of Pursed Lip Breathing on Exercise Capacity and Dyspnea in Patients With Interstitial Lung Disease: A RANDOMIZED, CROSSOVER STUDY. Journal of Cardiopulmonary Rehabilitation and Prevention 2019;39:112-7. [DOI: 10.1097/hcr.0000000000000387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
10 Karanth MS, Awad NT. Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res 2017;11:OC34-8. [PMID: 28571188 DOI: 10.7860/JCDR/2017/24707.9723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
11 Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Bendstrup E. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res 2020;21:91. [PMID: 32316976 DOI: 10.1186/s12931-020-01359-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Judson MA, Morgenthau AS, Baughman RP. Sarcoidosis. Murray and Nadel's Textbook of Respiratory Medicine. Elsevier; 2016. pp. 1188-1206.e7. [DOI: 10.1016/b978-1-4557-3383-5.00066-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Kaleth AS, Slaven JE, Ang DC. Determining the Minimal Clinically Important Difference for 6-Minute Walk Distance in Fibromyalgia. Am J Phys Med Rehabil 2016;95:738-45. [PMID: 27003201 DOI: 10.1097/PHM.0000000000000485] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
14 Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D. Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's "Q and A" approach. Pulm Pharmacol Ther 2017;42:21-4. [PMID: 27979760 DOI: 10.1016/j.pupt.2016.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
15 da Fontoura FF, Berton DC, Watte G, Florian J, Schio SM, Camargo JDJP, Teixeira PJZ, Moreira JDS. Pulmonary Rehabilitation in Patients With Advanced Idiopathic Pulmonary Fibrosis Referred for Lung Transplantation. Journal of Cardiopulmonary Rehabilitation and Prevention 2018;38:131-4. [DOI: 10.1097/hcr.0000000000000315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine 2022;196:106801. [DOI: 10.1016/j.rmed.2022.106801] [Reference Citation Analysis]
17 Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther 2014;8:875-85. [PMID: 25061279 DOI: 10.2147/DDDT.S64907] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
18 Kozu R, Jenkins S, Senjyu H. Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council dyspnea grade. Arch Phys Med Rehabil 2014;95:950-5. [PMID: 24502840 DOI: 10.1016/j.apmr.2014.01.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
19 Barreiro E, Bustamante V, Cejudo P, Gáldiz JB, Gea J, de Lucas P, Martínez-llorens J, Ortega F, Puente-maestu L, Roca J, Rodríguez González-moro JM. Guidelines for the Evaluation and Treatment of Muscle Dysfunction in Patients With Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumología (English Edition) 2015;51:384-95. [DOI: 10.1016/j.arbr.2015.04.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cantarero-Villanueva I, Postigo-Martin P, Granger CL, Waterland J, Galiano-Castillo N, Denehy L. The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments. Disabil Rehabil 2022;:1-8. [PMID: 35352996 DOI: 10.1080/09638288.2022.2043461] [Reference Citation Analysis]
21 Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 2018;19:182. [PMID: 30236104 DOI: 10.1186/s12931-018-0884-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
22 Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED TRIAL. J Cardiopulm Rehabil Prev 2018;38:124-30. [PMID: 29401114 DOI: 10.1097/HCR.0000000000000307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
23 Weir NA, Brown AW, Shlobin OA, Smith MA, Reffett T, Battle E, Ahmad S, Nathan SD. The Influence of Alternative Instruction on 6-Min Walk Test Distance. Chest 2013;144:1900-5. [DOI: 10.1378/chest.13-0287] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
24 Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Lung 2015;193:345-54. [DOI: 10.1007/s00408-015-9703-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
25 Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109:914-922. [PMID: 25956020 DOI: 10.1016/j.rmed.2015.04.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
26 Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med 2017;17:104. [PMID: 28743305 DOI: 10.1186/s12890-017-0444-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
27 Kang M, Veeraraghavan S, Martin GS, Kempker JA. An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Res 2021;7:00142-2021. [PMID: 34671666 DOI: 10.1183/23120541.00142-2021] [Reference Citation Analysis]
28 Sherbini N, Feteih MN, Wali SO, Alamoudi OS, Al-Faifi SM, Khalid I. Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med 2014;9:168-72. [PMID: 24987477 DOI: 10.4103/1817-1737.134073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med 2018;197:644-52. [PMID: 29099620 DOI: 10.1164/rccm.201709-1845OC] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 7.8] [Reference Citation Analysis]
30 Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011;18:283-7. [PMID: 21969931 DOI: 10.1155/2011/109635] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
31 Lee AL, Hill CJ, Cecins N, Jenkins S, McDonald CF, Burge AT, Rautela L, Stirling RG, Thompson PJ, Holland AE. Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training. Respir Med 2014;108:1303-9. [PMID: 25087836 DOI: 10.1016/j.rmed.2014.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
32 Luckhardt TR, Müller-Quernheim J, Thannickal VJ. Update in diffuse parenchymal lung disease 2011. Am J Respir Crit Care Med 2012;186:24-9. [PMID: 22753686 DOI: 10.1164/rccm.201203-0509UP] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Kenn K, Gloeckl R, Soennichsen A, Sczepanski B, Winterkamp S, Boensch M, Welte T. Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. Transplantation. 2015;99:1072-1077. [PMID: 25393161 DOI: 10.1097/tp.0000000000000472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
34 Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014;20:463-71. [PMID: 25022315 DOI: 10.1097/MCP.0000000000000091] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
35 Salih GN, Shaker SB, Madsen HD, Bendstrup E. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J 2016;3:32608. [PMID: 27616539 DOI: 10.3402/ecrj.v3.32608] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
36 Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I, Andrisani D, Cerri S, Luppi F, Fantini R, Marchioni A, Beghè B, Gigliotti F, Clini EM. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med 2017;17:130. [PMID: 29017478 DOI: 10.1186/s12890-017-0476-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
37 Maher TM. A Clinical Approach to Diffuse Parenchymal Lung Disease. Immunology and Allergy Clinics of North America 2012;32:453-72. [DOI: 10.1016/j.iac.2012.08.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8. [PMID: 20484178 DOI: 10.1056/NEJMoa1002110] [Cited by in Crossref: 366] [Cited by in F6Publishing: 141] [Article Influence: 30.5] [Reference Citation Analysis]
39 Majewski S, Szewczyk K, Żal A, Białas AJ, Miłkowska-Dymanowska J, Piotrowski WJ. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. J Clin Med 2021;10:3864. [PMID: 34501312 DOI: 10.3390/jcm10173864] [Reference Citation Analysis]
40 Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease. Respir Med 2018;138:32-7. [PMID: 29724390 DOI: 10.1016/j.rmed.2018.03.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Gloeckl R, Heinzelmann I, Seeberg S, Damisch T, Hitzl W, Kenn K. Effects of complementary whole-body vibration training in patients after lung transplantation: A randomized, controlled trial. J Heart Lung Transplant 2015;34:1455-61. [PMID: 26279196 DOI: 10.1016/j.healun.2015.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
42 Buzan MT, Pop CM. State of the art in the diagnosis and management of interstitial lung disease. Clujul Med 2015;88:116-23. [PMID: 26528058 DOI: 10.15386/cjmed-457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
43 Eves ND, Koelwyn GJ. Short of breath, short of benefit: important considerations for the rehabilitation of IPF patients. Respirology 2011;16:1163-4. [PMID: 21883682 DOI: 10.1111/j.1440-1843.2011.02055.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Lancaster L, Fieuw A, Meulemans J, Ford P, Nathan SD. Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemp Clin Trials 2021;100:106227. [PMID: 33246099 DOI: 10.1016/j.cct.2020.106227] [Reference Citation Analysis]
45 Täger T, Hanholz W, Cebola R, Fröhlich H, Franke J, Doesch A, Katus HA, Wians FH, Frankenstein L. Minimal important difference for 6-minute walk test distances among patients with chronic heart failure. International Journal of Cardiology 2014;176:94-8. [DOI: 10.1016/j.ijcard.2014.06.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
46 Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012;185:1147-53. [PMID: 22366047 DOI: 10.1164/rccm.201108-1420PP] [Cited by in Crossref: 92] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
47 Swigris JJ, Fairclough DL, Morrison M, Make B, Kozora E, Brown KK, Wamboldt FS. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care 2011;56:783-9. [PMID: 21333082 DOI: 10.4187/respcare.00939] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
48 Dubrock HM, Krowka MJ, Krok K, Forde K, Mottram C, Scanlon P, Al‐naamani N, Patel M, Mccormick A, Fallon MB, Kawut SM. Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates. Liver Transpl 2020;26:989-99. [DOI: 10.1002/lt.25794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Vainshelboim B. Clinical Improvement and Effectiveness of Exercise-Based Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis: A BRIEF ANALYTICAL REVIEW. J Cardiopulm Rehabil Prev 2021;41:52-7. [PMID: 33186196 DOI: 10.1097/HCR.0000000000000544] [Reference Citation Analysis]
50 Prior TS, Hoyer N, Shaker SB, Davidsen JR, Hilberg O, Patel H, Bendstrup E. Validation of a derived version of the IPF-specific Saint George's Respiratory Questionnaire. Respir Res 2021;22:259. [PMID: 34610840 DOI: 10.1186/s12931-021-01853-2] [Reference Citation Analysis]
51 Bernstein WK. Pulmonary function testing. Current Opinion in Anaesthesiology 2012;25:11-6. [DOI: 10.1097/aco.0b013e32834e7ad2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
52 Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015;11:359-70. [PMID: 25767391 DOI: 10.2147/TCRM.S69716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
53 Portincasa P, Di Ciaula A, Wang DQ. Longer Walking Distance, More Fat, Better Survival: Prognostic Indicators of Liver Cirrhosis. J Gastrointestin Liver Dis 2021;30:8-12. [PMID: 33723545 DOI: 10.15403/jgld-3455] [Reference Citation Analysis]
54 Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty K, Sood R, O'riordan TG, Lynch DA. Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. Eur Respir J 2018;52:1801384. [DOI: 10.1183/13993003.01384-2018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
55 Doyle TJ, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Divo MJ, Celli BR, Sciurba FC, Silverman EK, Hatabu H, Rosas IO, Hunninghake GM; COPDGene Investigators. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012;185:756-62. [PMID: 22268134 DOI: 10.1164/rccm.201109-1618OC] [Cited by in Crossref: 71] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
56 Bajwah S, Ross JR, Peacock JL, Higginson IJ, Wells AU, Patel AS, Koffman J, Riley J. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax 2013;68:867-79. [DOI: 10.1136/thoraxjnl-2012-202040] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
57 Gan Y, Herzog EL, Gomer RH. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2011;7:39-47. [PMID: 21339942 DOI: 10.2147/TCRM.S12209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
58 Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010;11:89. [PMID: 20584284 DOI: 10.1186/1465-9921-11-89] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
59 Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016;48:843-51. [DOI: 10.1183/13993003.01966-2015] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 13.5] [Reference Citation Analysis]
60 Naz I, Sahin H, Demirci Uçsular F, Yalnız E. A comparison trial of eight weeks versus twelve weeks of exercise program in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2018;35:299-307. [PMID: 32476917 DOI: 10.36141/svdld.v35i4.6830] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology 2018;23:1041-8. [PMID: 30011421 DOI: 10.1111/resp.13365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
62 du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183:1231-1237. [PMID: 21131468 DOI: 10.1164/rccm.201007-1179oc] [Cited by in Crossref: 247] [Cited by in F6Publishing: 92] [Article Influence: 20.6] [Reference Citation Analysis]
63 Lyseng-Williamson KA. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). BioDrugs 2014;28:465-75. [PMID: 25200032 DOI: 10.1007/s40259-014-0108-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
64 Puente Maestú L, García de Pedro J. Lung function tests in clinical decision-making. Arch Bronconeumol 2012;48:161-9. [PMID: 22364671 DOI: 10.1016/j.arbres.2011.12.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, Morisset J, Fell C, Fisher JH, Manganas H, Shapera S, Cox G, Gershon AS, Hambly N, Khalil N, To T, Wilcox PG, Halayko A, Kolb MR, Ryerson CJ. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax 2021;76:37-43. [PMID: 33023996 DOI: 10.1136/thoraxjnl-2020-214944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
66 Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;189:770-8. [PMID: 24547893 DOI: 10.1164/rccm.201312-2219PP] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
67 Lancaster L, Goldin J, Trampisch M, Kim GH, Ilowite J, Homik L, Hotchkin DL, Kaye M, Ryerson CJ, Mogulkoc N, Conoscenti CS. Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respir Med J 2020;14:22-31. [PMID: 33088361 DOI: 10.2174/1874306402014010022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Schrover R, Evans K, Giugliani R, Noble I, Bhattacharya K. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome. Orphanet J Rare Dis 2017;12:78. [PMID: 28441951 DOI: 10.1186/s13023-017-0633-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
69 Majewski S, Szewczyk K, Jerczyńska H, Miłkowska-Dymanowska J, Białas AJ, Gwadera Ł, Piotrowski WJ. Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis. Front Immunol 2022;13:760776. [PMID: 35222369 DOI: 10.3389/fimmu.2022.760776] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Keyser RE, Woolstenhulme JG, Chin LM, Nathan SD, Weir NA, Connors G, Drinkard B, Lamberti J, Chan L. Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm Rehabil Prev 2015;35:47-55. [PMID: 25313451 DOI: 10.1097/HCR.0000000000000083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
71 Houchen-Wolloff L, Evans RA. Unravelling the mystery of the 'minimum important difference' using practical outcome measures in chronic respiratory disease. Chron Respir Dis 2019;16:1479973118816491. [PMID: 30789024 DOI: 10.1177/1479973118816491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
72 Lancaster LH. Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2018;13:45. [PMID: 30559965 DOI: 10.1186/s40248-018-0158-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
73 Barreiro E, Bustamante V, Cejudo P, Gáldiz JB, Gea J, de Lucas P, Martínez-Llorens J, Ortega F, Puente-Maestu L, Roca J, Rodríguez-González Moro JM; SEPAR. Guidelines for the evaluation and treatment of muscle dysfunction in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2015;51:384-95. [PMID: 26072153 DOI: 10.1016/j.arbres.2015.04.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
74 Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044-8. [PMID: 22505745 DOI: 10.1164/rccm.201201-0006PP] [Cited by in Crossref: 155] [Cited by in F6Publishing: 60] [Article Influence: 15.5] [Reference Citation Analysis]
75 Brown AW, Nathan SD. The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. Annals ATS 2018;15:3-10. [DOI: 10.1513/annalsats.201703-244fr] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
76 Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR, Garvey C. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 2014;108:203-10. [PMID: 24332409 DOI: 10.1016/j.rmed.2013.11.016] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 11.2] [Reference Citation Analysis]
77 Patel AS, Siegert RJ, Keir GJ, Bajwah S, Barker RD, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013;107:1438-43. [PMID: 23867809 DOI: 10.1016/j.rmed.2013.06.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
78 Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung 2012;190:523-7. [PMID: 22810758 DOI: 10.1007/s00408-012-9410-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
79 Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Morán-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Ann Am Thorac Soc 2016;13:1640-7. [PMID: 27348402 DOI: 10.1513/AnnalsATS.201604-267OC] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 7.3] [Reference Citation Analysis]
80 Zhou M, Zhang H, Li F, Yu Z, Yuan C, Oliver B, Li J. Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: A randomized controlled trial. Respirology 2021;26:360-9. [PMID: 33164264 DOI: 10.1111/resp.13972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Kang M, Marts L, Kempker JA, Veeraraghavan S. Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe (Sheff) 2021;17:200345. [PMID: 34295421 DOI: 10.1183/20734735.0345-2020] [Reference Citation Analysis]
82 de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respiratory Medicine 2011;105:1388-95. [DOI: 10.1016/j.rmed.2011.05.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
83 Baran SW, Gupta AD, Lim MA, Mathur A, Rowlands DJ, Schaevitz LR, Shanmukhappa SK, Walker DB. Continuous, Automated Breathing Rate and Body Motion Monitoring of Rats With Paraquat-Induced Progressive Lung Injury. Front Physiol 2020;11:569001. [PMID: 33178039 DOI: 10.3389/fphys.2020.569001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012;106:1447-55. [PMID: 22801586 DOI: 10.1016/j.rmed.2012.06.018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
85 Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, Mccormack MC, Macintyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1447-78. [DOI: 10.1183/09031936.00150414] [Cited by in Crossref: 343] [Cited by in F6Publishing: 313] [Article Influence: 42.9] [Reference Citation Analysis]
86 Kostorz-nosal S, Jastrzębski D, Kubicki P, Galle D, Gałeczka-turkiewicz A, Toczylowska B, Ziora D. Forced Oscillation Measurements in Patients with Idiopathic Interstitial Pneumonia Subjected to Pulmonary Rehabilitation. JCM 2022;11:3657. [DOI: 10.3390/jcm11133657] [Reference Citation Analysis]
87 Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23:377-381. [PMID: 27592691 DOI: 10.1111/jep.12629] [Cited by in Crossref: 168] [Cited by in F6Publishing: 166] [Article Influence: 28.0] [Reference Citation Analysis]